Gapping up
In reaction to strong earnings/guidance:
In reaction to strong earnings/guidance:
- DO +9.1%, IRMD +5.9%, SONS +4.9%, URG +1.9%, EDR +1.1%, L +0.6%
M&A news:
- AVIR +25.3% (Vaxart and Aviragen Therapeutics enter merger agreement)
- CAA +19.2% (CalAtlantic Group and Lennar (LEN) announce merger (80% stock and 20% cash), implied value of the stock consideration is $51.34 per share)
- DYN +13.8% (Dynegy and Vistra Energy (VST) to merge in all-stock transaction; DYN shareholders will receive 0.652 shares of VST stock)
- AAAP +9.9% (receives tender offer by Novartis (NVS) for $82 per share)
Other news:
- MICT +36.8% (received a purchase order valued at approximately $3,100,000 for its recently released SmartHub-TREQr5 product)
- SOHU +3.7% (subsidiary Sogou filed amendment relating to an IPO)
- PTIE +3.1% (FDA has agreed to a pre-NDA guidance meeting to discuss its NDA resubmission for REMOXY ER)
- SRRA +2.8% (reports preclinical data supporting the ongoing clinical development strategy for its Chk1 inhibitor, SRA737)
- BMY +2.7% (benefitting from MRK withdrawal of its European application for KEYTRUDA)
- SHPG +1.3% (Barron's profiles positive view on Shire)
- CELG +1.3% (reports Second Phase III Trial for Ozanimod demonstrating superiority versus Avonex)
- AVXL +1% (announces additional data for ANAVEX2-73)
Analyst comments:
- ADMS +16.6% (initiated with a Outperform at Evercore ISI (settled at $19.51 on Friday))
- JD +1.4% (upgraded to Buy from Neutral at UBS)
- WETF +1.2% (added to US Focus List at Citigroup)
- CAG +0.8% (upgraded to Buy from Hold at Stifel)
- INTC +0.5% (upgraded to Outperform from Market Perform at BMO Capital Markets)